Clinical trial
PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate…
NCT00291005 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00291005 |
|---|---|
| Title | PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone |
| Official title | A Multicenter Phase II Open Label Non-Comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | ARD6562, Docetaxel |
| Enrollment | 42 |
| Start date | Aug 1, 2004 |
| First posted | Feb 13, 2006 |
| Last update posted | Mar 27, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: